pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - agenti antineoplastici - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
blincyto
amgen europe b.v. - blinatumomab - linfoma di leucemia linfoblastica a cellule precursori - agenti antineoplastici - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
ketorolac baxter
baxter holding bv - ketorolac - ketorolac
glucosio baxter s.p.a.
baxter s.p.a. - altri additivi per soluzioni endovena - altri additivi per soluzioni endovena
glucosio baxter s.p.a.
baxter s.p.a. - levulosio soluzioni - levulosio soluzioni
elettrolitica reidratante baxter
baxter s.p.a. - elettroliti - elettroliti
atorvastatina alter
laboratori alter s.r.l. - atorvastatina - atorvastatina
telmisartan e idroclorotiazide alter
laboratori alter s.r.l. - telmisartan - telmisartan
endoxan baxter
baxter s.p.a. - ciclofosfamide - ciclofosfamide
olmesartan medoxomil e idroclorotiazide alter
laboratori alter s.r.l. - olmesartan medoxomil e diuretici - olmesartan medoxomil e diuretici